

3

Docket No. GJE-70
Serial No. 09/868,352In the Claims

Claims 1-30 (Cancelled)

Claim 31 (Currently amended): A method for the treatment of a condition associated with Group B Streptococcal infection caused by Streptococcus agalactiae, wherein said method comprises administering to a patient an effective amount of a an isolated peptide comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23 or an isolated peptide comprising the immunogenic portion of SEQ ID NO: 23, wherein said immunogenic portion induces an immune response and selectively binds to anti-Streptococcus agalactiae antibody specific for SEQ ID NO: 23.

Claim 32 (Cancelled)

Claim 33 (Currently amended): The method according to claim 31, wherein said peptide comprises comprising the amino acid sequence of SEQ ID NO:23 is administered to the patient.

Claim 34 (Cancelled)

Claim 35 (Previously added): The method according to claim 31, wherein the infection is a local infection.

Claim 36 (Previously added): The method according to claim 31, wherein the infection is a urinary tract infection.

Claim 37 (Currently amended): A method for the prevention of a condition associated with Group B Streptococcal infection caused by Streptococcus agalactiae, wherein said method comprises

J:\GJE\70\Amend-Resp\SuppAmend\AF.doc/DNB/mv

4

Docket No. GJE-70
Serial No. 09/868,352

administering to a patient an effective amount of a an isolated peptide comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23 or an isolated peptide comprising the immunogenic portion of SEQ ID NO: 23, wherein said immunogenic portion induces an immune response and selectively binds to anti-Streptococcus agalactiae antibody specific for SEQ ID NO: 23.

Claim 38 (Cancelled)

Claim 39 (Currently amended): The method according to claim 37, wherein said peptide comprises comprising the amino acid sequence of SEQ ID NO:23 is administered to the patient.

Claim 40 (Cancelled)

Claim 41 (Previously added): The method according to claim 37, wherein the infection is a local infection.

Claim 42 (Previously added): The method according to claim 37, wherein the infection is a urinary tract infection.

J:\GJE\70\Amend-Resp\SuppAmendAF.doc\DNF\mv